Welcome to our dedicated page for Apollomics Warrant news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on Apollomics Warrant stock.
Apollomics Inc is a clinical-stage biopharmaceutical company dedicated to developing oncology therapies that can be combined with other treatments to target the immune system and molecular pathways for cancer treatment. Their lead programs, vebreltinib (APL-101) and uproleselan (APL-106), show promising results in treating various cancers.
Rhea-AI Summary
Apollomics Inc. announces the approval of Vebreltinib in China for the treatment of gliomas with MET fusion gene, making it the world's first c-Met inhibitor approved for CNS tumors. The approval is based on a Phase 2/3 trial. The collaboration with Avistone and the global SPARTA trial highlight the potential of Vebreltinib in treating solid tumors with c-Met alterations globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
-
Rhea-AI Summary
Apollomics Inc. presents preclinical data on vebreltinib showing efficacy in treating various tumor types with MET-driver alterations and overcoming resistance in EGFR-positive non-small cell lung cancer at the AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research Annual Meeting. The presentations showcase the mechanism of action and anti-tumor activity of vebreltinib in diverse patient-derived tumor models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
Rhea-AI Summary
Apollomics Inc. (APLM) reports continued clinical and regulatory progress for vebreltinib and completion of patient enrollment for uproleselan Phase 3 study in China. The company has $37.8 million in cash as of December 31, 2023, with a cash runway till Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.97%
Tags
-
News
Rhea-AI Summary
Apollomics Inc. will announce its full year 2023 financial results on March 28, 2024, followed by a conference call and webcast. The management team will discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
-
Rhea-AI Summary
Apollomics Inc. appoints Matthew Plunkett, Ph.D., as Chief Financial Officer to drive financial strategy and business development. Dr. Plunkett brings over 25 years of experience in the biopharmaceutical sector, enhancing Apollomics' growth and clinical trial progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, Ph.D., and President Sanjeev Redkar, Ph.D., will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The presentation will be accessible via live webcast and a replay will be available. Investors can arrange meetings with the company's management during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.43%
Tags
-
Rhea-AI Summary
Apollomics Inc. received a notification from Nasdaq stating that the company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share. The company has 180 days to regain compliance, with the possibility of an additional 180-day period if needed. Failure to regain compliance may lead to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary
Apollomics Inc. announced that its Chairman and CEO, Guo-Liang Yu, and President, Sanjeev Redkar, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference. The event will take place on January 18, 2024, at 11:00 a.m. ET. The live webcast will be accessible through B. Riley Securities, and an archived replay will be available on the Apollomics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
Rhea-AI Summary
Apollomics Inc. (Nasdaq: APLM) completes enrollment in Phase 3 bridging study for uproleselan in relapsed or refractory acute myeloid leukemia patients in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
FAQ
What is the current stock price of Apollomics Warrant (APLMW)?
The current stock price of Apollomics Warrant (APLMW) is $0.0108 as of November 4, 2024.
What is the market cap of Apollomics Warrant (APLMW)?
The market cap of Apollomics Warrant (APLMW) is approximately 27.9M.
What is Apollomics Inc focused on?
Apollomics Inc focuses on developing oncology therapies that target the immune system and molecular pathways for cancer treatment.
What are Apollomics Inc lead programs?
Apollomics Inc lead programs include vebreltinib (APL-101) and uproleselan (APL-106) which show promising results in treating various cancers.
What is vebreltinib (APL-101) used for?
vebreltinib (APL-101) is a potent, selective c-Met inhibitor used in the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations.
What is uproleselan (APL-106)?
uproleselan (APL-106) is a specific E-Selectin antagonist that could be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
How effective is vebreltinib in treating different tumor types?
Preclinical studies have shown that vebreltinib is effective for a variety of tumor types carrying MET-driver alterations.
What do Phase 2 and 2/3 trials demonstrate about vebreltinib?
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations.
How can I contact Apollomics Inc for Investor Relations?
For Investor Relations, you can contact Peter Vozzo at ICR Westwicke by email at Peter.Vozzo@westwicke.com or phone at +1-443-213-0505.
How can I contact Apollomics Inc for Media Relations?
For Media Relations, you can contact Sean Leous at ICR Westwicke by email at Sean.Leous@westwicke.com or phone at +1-646-866-4012.
Apollomics Inc. Warrant
Nasdaq:APLMW
APLMW Rankings
APLMW Stock Data
27.88M
109.97M
United States of America